Viscosupplementation

Global Viscosupplementation Market to Reach US$8.8 Billion by 2030

The global market for Viscosupplementation estimated at US$5.6 Billion in the year 2024, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 7.9% over the analysis period 2024-2030. Single Injection, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$4.9 Billion by the end of the analysis period. Growth in the Three Injection segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.6% CAGR

The Viscosupplementation market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Viscosupplementation Market - Key Trends & Drivers Summarized

Why Is Viscosupplementation Becoming a Preferred Treatment for Osteoarthritis?
Viscosupplementation has emerged as a widely adopted, minimally invasive treatment for knee osteoarthritis (OA), providing pain relief and improved joint mobility for patients suffering from degenerative joint conditions. The procedure involves injecting hyaluronic acid (HA) into the synovial fluid, enhancing lubrication and reducing friction within the joint. With the rising prevalence of osteoarthritis, particularly among the aging population, viscosupplementation is being increasingly recommended as an alternative to pain medication and surgical interventions. Furthermore, the growing preference for non-surgical pain management solutions has led to heightened demand for HA-based injections across orthopedic clinics and hospitals.

How Are Technological Innovations Enhancing Viscosupplementation Therapies?
The viscosupplementation market is witnessing advancements in HA formulation, improving the efficacy and durability of treatment. Innovations such as cross-linked and high-molecular-weight HA injections have enhanced the viscosity and longevity of synovial fluid replacement, providing prolonged pain relief for osteoarthritis patients. Additionally, the development of single-injection therapies is gaining traction, reducing the need for multiple treatment sessions and improving patient compliance. Companies are also investing in novel drug-delivery systems and bioengineered HA derivatives to enhance treatment outcomes and minimize adverse effects.

What Are the Key Market Trends Shaping Viscosupplementation Adoption?
The increasing focus on early intervention and preventive healthcare is driving the adoption of viscosupplementation as a first-line treatment for knee osteoarthritis. Rising awareness about joint health and mobility preservation, especially among middle-aged individuals and athletes, is further fueling demand for HA injections. Additionally, the growing integration of regenerative medicine approaches, such as platelet-rich plasma (PRP) therapy in combination with HA injections, is expanding the therapeutic scope of viscosupplementation. Insurance coverage and reimbursement policies for osteoarthritis treatments are also evolving, making viscosupplementation more accessible to patients worldwide.

What Factors Drive the Growth of the Market?

The growth in the viscosupplementation market is driven by several factors, including the increasing prevalence of osteoarthritis, advancements in HA-based formulations, and the rising demand for non-surgical pain management solutions. The shift towards minimally invasive treatments is propelling the adoption of single-injection and cross-linked HA therapies. Additionally, improvements in healthcare infrastructure and expanding insurance coverage are making viscosupplementation more widely available. The integration of regenerative medicine techniques, coupled with increasing patient awareness of early-stage osteoarthritis management, is further contributing to market expansion.

SCOPE OF STUDY:

The report analyzes the Viscosupplementation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Segment (Single Injection, Three Injection, Five Injection)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

• Allergan PLC
• Anika Therapeutics SRL
• Contipro a.s.
• DePuy Synthes
• F. Hoffmann-La Roche AG
• Ferring Pharmaceuticals, Inc.
• Galderma SA
• Lifecore Biomedical LLC
• Merz Aesthetics
• Mylan Pharmaceutical Pvt. Ltd.
• Nordic Drugs
• Sanofi SA
• Shanghai Jingfeng Pharmaceutical Co., Ltd
• Smith & Nephew PLC
• TRB Chemedica International SA

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.